Naratriptan

International Journal of Clinical Practice

Volumn 53, Issue 7, 1999, Pages 552-556

  Salonen, Reijo ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; SEROTONIN AGONIST; SUMATRIPTAN;

DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INTRANASAL DRUG ADMINISTRATION; MIGRAINE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECTAL DRUG ADMINISTRATION; SHORT SURVEY; SIDE EFFECT;

ADOLESCENT; ADULT; AGED; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PIPERIDINES; RECURRENCE; SEROTONIN AGONISTS; TRYPTAMINES;

EID: 0032697322     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (23)

1. Lipton RB, Stewart WF. The epidemiology of migraine. Eur Neurol 1994; 34(suppl 2): 6-11.
2. Staffa JA, Lipton RB, Stewart WF. The epidemiology of migraine headache. Rev Contemp Pharmacother 1994; 5: 241-252.
3. Bates D, Bradbury P, Capildeo R et al. Migraine management guidelines: a strategy for the modern management of migraine. London: Synergy Medical Education, 1997.
4. Humphrey PPA, Feniuk W, Marriott AS et al. Preclinical studies on the anti-migraine drug, sumatriptan. Eur Neurol 1991; 31: 282-290.
5. Moskowitz M, Macfarlane R. Neurovascular and molecular mechanisms in migraine headache. Cerobrovasc Brain Metab Rev 1993; 5: 159-177.
6. Pilgrim AJ, Blakeborough P. The clinical efficacy of sumatriptan in the acute treatment of migraine. Rev Contemp Pharmacother 1994; 5: 295-309.
7. Mushet GR, Cady RK, Baker CC et al. Efficacy and tolerability of subcutaneous sumatriptan administered using the IMITREX STATdose System. Clin Ther 1996; 18; 687-699.
8. Pfaffenrath V, Cunin G, Sjonell G et al. Efficacy and safety of sumatriptan tablets in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache 1998; 38: 184-190.
9. Ryan R et al. Sumatriptan nasal spray for the acute treatment of migraine: results of two clinical studies. Neurology 1997; 49: 1225-1230.
10. Jhingran P, Cady RK, Rubino J et al. Improvements in health-related quality of life with sumatriptan treatment for migraine. J Fam Pract 1996; 42: 36-42.
11. Mathew NT. Serotonin 1(D) (5-HT[1D]) agonists and other agents in acute migraine. Neurol Clin 1997; 15: 61-83.
12. Simmons VE, Blakeborough P. The safety profile of sumatriptan. Rev Contemp Pharmacother 1994; 5: 319-328.
13. Connor HE, Feniuk W, Beattie DT et al. Naratriptan: biological profile in animal models relevant to migraine. Cephalalgia 1997; 17: 145-152.
14. 1D agonist drugs: selectively targeting additional sites of action. Eur Neurol 1996; 36(suppl 2): 13-18.
15. Goadsby P. Is a central action of acute antimigraine drugs essential? Cephalalgia 1997; 17(suppl): 10-11.
16. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8: 1-96.
17. Dahlof C, Winter P, Whitehouse H et al. Randomized, double-blind, placebo-controlled comparison of oral naratriptan and oral sumatriptan in the acute treatment of migraine. Neurology 1997; 48(suppl 2): A85-A86.
18. Klassen A, Elkind A, Asgharnejad M et al. Naratriptan is effective and well tolerated in the acute treatment of migraine: results of a double-blind, placebo-controlled, parallel-group study. Headache 1997; 37(10): 640-645.
19. Mathew NT, Asgharnejad M, Peykamian M, Laurenza A. Naratriptan is effective and well tolerated in the acute treatment of migraine: results of a double-blind, placebo-controlled, crossover study. Neurology 1997; 49(6): 1485-1490.
20. Bates D, Winter P. Efficacy and tolerability of naratriptan tablets (0.1 mg-2.5 mg) in the acute treatment of migraine. Eur J Neurol 1998; 5(suppl 3): S48-S49.
21. Bomhof MA, Heywood J, Pradalier A et al. Tolerability and efficacy of naratriptan tablets with long-term treatment (6 months). Cephalalgia 1998; 18: 33-37.
22. Zagami AS. 311C90 (zolmitriptan): long term efficacy and tolerability profile for the acute treatment of migraine. Neurology 1997; 48(suppl 3): S25-S28.
23. The first comparison of the efficacy and safety of 311C90 and sumatriptan in the treatment of migraine. Poster presented at the 3rd Congress of the European Headache Federation, Sardinia, 1996.